Fundraising Amyl Therapeutics

THM Capital Advisory advises Amyl Therapeutics on its €8.4 million financing round, including €4 million in equity and €4.4 million in non-dilutive funding.

‍

Company overview

Amyl Therapeutics is a Belgian biotechnology company developing a first-in-class therapy for Alzheimer’s disease and other neurodegenerative disorders. The company is developing an innovative fusion protein designed to simultaneously target the three pathogenic proteins involved in these diseases: amyloid-β, Tau and α-synuclein.

‍

Transaction rationale

This €8.4 million financing round, comprising €4 million in equity and €4.4 million in non-dilutive funding granted by the Walloon Region, will enable Amyl Therapeutics to continue optimizing its therapeutic candidate, select its lead candidate and fund the next stages of preclinical validation through in vivo proof of concept.
‍

Investors

Family offices, private investors and existing shareholders, including the Mérieux and Noshaq investment funds.